Trials / Completed
CompletedNCT00114049
Dental Pain (Following Third Molar Tooth Extraction) Study
A Pivotal Phase III, Single Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Investigate the Efficacy and Safety of Single Oral Doses of 10mg, 25mg, 50mg and 70mg GW406381 and 550mg Naproxen Sodium in Subjects With Pain Following Third Molar Tooth Extraction
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 300 (planned)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effectiveness of GW406381 (a COX-2 inhibitor) in treating the signs and symptoms of dental pain following third molar tooth extraction.
Detailed description
A Pivotal Phase III, Single Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Investigate the Efficacy and Safety of Single Oral Doses of 10mg, 25mg, 50mg, and 70mg GW406381 and 550mg Naproxen Sodium in Subjects With Pain Following Third Molar Tooth Extraction
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GW406381 |
Timeline
- Start date
- 2004-12-01
- Primary completion
- 2005-04-01
- Completion
- 2005-04-01
- First posted
- 2005-06-14
- Last updated
- 2017-01-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00114049. Inclusion in this directory is not an endorsement.